Inhibition of trans-plasma membrane electron transport: A potential anti-leukemic strategy

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1630-1635

  Prata, Cecilia ^a   Grasso, Carole ^b   Loizzo, Stefano ^c   Sega, Francesco Vieceli Dalla ^a   Caliceti, Cristiana ^a   Zambonin, Laura ^a   Fiorentini, Diana ^a   Hakim, Gabriele ^a   Berridge, Michael V ^b   Landi, Laura ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antitumor compounds; Glycolytic cancer cells; Leukemic cell proliferation; NAD(P)H autofluorescence; Trans plasma membrane electron transport

Indexed keywords

2 CHLORO 6 (2,5 DIMETHOXY 4 NITROPHENYL)IMIDAZO[2,1 B]THIAZOLE 5 CARBALDEHYDE GUANYLHYDRAZONE; 3 (2 CHLORO 5 METHOXY 6 METHYL 3 INDOLYLMETHYLENE) 5 HYDROXY 1,3 DIHYDROINDOL 2 ONE; 3 [(2,6 DIMETHYLIMIDAZO[2,1 B]THIAZOL 5 YL)METHYLENE] 5 METHOXY 2 INDOLINONE; 6 (2,5 DIMETHOXY 4 NITROPHENYL)IMIDAZO[2,1 B]THIAZOLE 5 CARBALDEHYDE GUANYLHYDRAZONE; ANTILEUKEMIC AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ELECTRON TRANSPORT; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; LEUKEMIA CELL LINE; MITOCHONDRIAL ENERGY TRANSFER; MITOSIS INHIBITION; MYELOID LEUKEMIA; PRIORITY JOURNAL; TRANS PLASMA MEMBRANE ELECTRON TRANSPORT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTRON TRANSPORT; HUMANS; LEUKEMIA; NAD;

EID: 78149358350     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.02.032     Document Type: Article

References (30)

1. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64:3892-3899.
2. Schornack P.A., Gillies R.J. Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia 2003, 5:135-145.
3. Simonnet H., Alazard N., Pfeiffer K., Gallou C., Béroud C., Demont J., et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002, 23:759-768.
4. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
5. Brand K. Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr 1997, 29:355-364.
6. Pedersen P.L. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978, 22:190-274.
7. Herst P.M., Berridge M.V. Plasma membrane electron transport: a new target for cancer drug development. Curr Mol Med 2006, 6:895-904.
8. Larm J.A., Vaillant F., Linnane A.W., Lawen A. Up-regulation of the plasma membrane oxidoreductase as a prerequisite for the viability of human Namalwa rho 0 cells. J Biol Chem 1994, 269:30097-30100.
9. Scarlett D.J., Herst P., Tan A., Prata C., Berridge M. Mitochondrial gene-knockout (rho0) cells: a versatile model for exploring the secrets of trans-plasma membrane electron transport. Biofactors 2004, 20:199-206.
10. Tan A.S., Berridge M.V. Distinct trans-plasma membrane redox pathways reduce cell-impermeable dyes in HeLa cells. Redox Rep 2004, 9:302-306.
11. Villalba J.M., Navas P. Plasma membrane redox system in the control of stress-induced apoptosis. Antioxid Redox Signal 2000, 2:213-230.
12. Herst P.M., Berridge M.V. Cell surface oxygen consumption: a major contributor to cellular oxygen consumption in glycolytic cancer cell lines. Biochim Biophys Acta 2007, 1767:170-177.
13. Berridge M.V., Herst P.M., Tan A.S. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 2005, 1:127-152.
14. 2. Free Radic Biol Med 2001, 31:923-931.
15. Fiorentini D., Prata C., Maraldi T., Zambonin L., Bonsi L., Hakim G., et al. Contribution of reactive oxygen species to the regulation of Glut1 in two hemopoietic cell lines differing in cytokine sensitivity. Free Radic Biol Med 2004, 37:1402-1411.
16. Bonsi L., Grossi A., Strippoli P., Tumietto F., Tonelli R., Vannucchi A.M., et al. An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo). Br J Haematol 1997, 98:549-559.
17. Martin P., Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 1982, 16:1233-1235.
18. Cole S.P. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 1986, 17:259-263.
19. Herst P.M., Davis J.E., Neeson P., Berridge M.V., Ritchie D.S. The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells. Haematologica 2009, 94:928-934.
20. Schuchmann S., Kovacs R., Kann O., Heinemann U., Buchheim K. Monitoring NAD(P)H autofluorescence to assess mitochondrial metabolic functions in rat hippocampal-entorhinal cortex slices. Brain Res Protocol 2001, 7:267-276.
21. Andreani A., Granaiola M., Leoni A., Locatelli A., Morigi R., Rambaldi M., et al. Substituted E-3-(2-Chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity. Bioorg Med Chem 2004, 12:1121-1128.
22. Andreani A., Granaiola M., Leoni A., Locatelli A., Morigi R., Rambaldi M., et al. Synthesis and antitumor activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones. Anticancer Drug Des 2001, 16:167-174.
23. Andreani A., Granaiola M., Leoni A., Locatelli A., Morigi R., Rambaldi M., et al. Potential antitumor agents. 37. Synthesis and antitumor activity of guanylhydrazones from imidazo[2,1-b]thiazoles and from the new heterocyclic system thiazolo[2′,3′:2,3]imidazo[4,5-c]quinoline. J Med Chem 2005, 48:3085-3089.
24. King M.P., Attardi G. Isolation of human cell lines lacking mitochondrial DNA. Methods Enzymol 1996, 264:304-313.
25. Gómez-Díaz C., Villalba J.M., Pérez-Vicente R., Crane F.L., Navas P. Ascorbate stabilization is stimulated in rho(0)HL-60 cells by CoQ10 increase at the plasma membrane. Biochem Biophys Res Commun 1997, 234:79-81.
26. Kunkel M., Reichert T.E., Benz P., Lehr H.A., Jeong J.H., Wieand S., et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003, 97:1015-1024.
27. Andreani A., Burnelli S., Granaiola M., Leoni A., Locatelli A., Morigi R., et al. Antitumor activity of bis-indole derivatives. J Med Chem 2008, 51:4563-4570.
28. Kamb A., Wee S., Lengauer C. Why is cancer drug discovery so difficult?. Nat Rev Drug Discov 2007, 6:115-120.
29. Olsen J., Overvad K. The concept of multifactorial etiology of cancer. Pharmacol Toxicol 1993, 72:33-38.
30. Morphy R., Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005, 48:6523-6543.